Author: | Zelenetz, A. D. |
Article Title: | Mantle cell lymphoma: An update on management |
Abstract: | Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with chemotherapy may provide a platform onto which rituximab or autologous stem cell transplantation can be added. Targeted therapies are also showing promise and may have a role in maintenance and/or initial therapy. © 2006 Oxford University Press. |
Keywords: | cancer survival; treatment failure; acute granulocytic leukemia; prednisone; clinical trial; doxorubicin; cancer growth; conference paper; alpha interferon; combined modality therapy; cytarabine; methotrexate; rituximab; drug megadose; antineoplastic agent; apoptosis; bortezomib; mantle cell lymphoma; etoposide; blood toxicity; antineoplastic combined chemotherapy protocols; maintenance therapy; antifungal agent; cyclophosphamide; dexamethasone; melphalan; vincristine; autologous stem cell transplantation; stem cell transplantation; antineoplastic activity; carmustine; temsirolimus; cancer regression; antiinfective agent; folinic acid; cancer relapse; flavopiridol; mesna; radioimmunotherapy; tositumomab i 131; lymphoma, mantle-cell; targeted therapies; myelodysplasia |
Journal Title: | Annals of Oncology |
Volume: | 17 |
Issue: | Suppl.4 |
ISSN: | 0923-7534 |
Publisher: | Oxford University Press |
Date Published: | 2006-05-01 |
Start Page: | iv12 |
End Page: | iv14 |
Language: | English |
DOI: | 10.1093/annonc/mdj992 |
PUBMED: | 16702178 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 16" - "Export Date: 4 June 2012" - "CODEN: ANONE" - "Source: Scopus" |